Thursday, July 01, 2021 3:52:40 PM
http://archive.fast-edgar.com/20210630/ACZID22CZ2228JZ2222H2ZZZ6Q22Z4ZI8232/
KOD had added another trial to cover once a month dosing .
They stated that the feedback they had from eye specialists is that the MD's wanted 1 drug for all applications ...1 mth out to 6 mth
So they had to add an extra trial for the 1 mth data .
This meant that the NDA would be delayed by at least 6 mths and the stock sold off significantly since that was announced.
The Baker Bros own around 28% of this Co. They would definitely had to be on board with this decision since they would take a significant short term hit.
Nice to see them adding to their position now.
The key DAZZLE trial is fully enrolled and on track for readout in Q1 2022
4 other trials to read out or be update in remainder of 2022.
Co has around $900m cash on hand so no risk of dilution near term
Kiwi
Recent KOD News
- Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results • PR Newswire (US) • 03/28/2024 10:30:00 AM
- Kodiak Sciences to Report Fourth Quarter and Full-Year 2023 Financial Results and Host Business Updates Webcast on March 28, 2024 • PR Newswire (US) • 03/26/2024 10:15:00 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:23:00 PM
- Kodiak Sciences Announces Upcoming Presentation of First Time Results of KSI-501ABC Phase 1 Study at the Angiogenesis, Exudation, and Degeneration 2024 Virtual Meeting • PR Newswire (US) • 01/30/2024 11:30:00 AM
- Kodiak Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference • PR Newswire (US) • 01/04/2024 09:15:00 PM
- Kodiak Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference • PR Newswire (US) • 11/21/2023 09:15:00 PM
- Kodiak Sciences Announces Third Quarter 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 11/14/2023 09:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 11:05:54 AM
- Kodiak reboots tarcocimab tedromer development program following strong positive results in Phase 3 diabetic retinopathy GLOW study and following dialogue with US regulatory authorities on a regulatory pathway for BLA submission • PR Newswire (US) • 11/06/2023 10:00:00 AM
- KODIAK SCIENCES ANNOUNCES FIRST TIME PRESENTATION OF PRIMARY ENDPOINT DATA FROM TARCOCIMAB TEDROMER PHASE 3 GLOW STUDY IN PATIENTS WITH DIABETIC RETINOPATHY AT AMERICAN ACADEMY OF OPHTHALMOLOGY ANNUAL MEETING • PR Newswire (US) • 11/02/2023 03:21:00 AM
- Kodiak Sciences Announces Upcoming Presentations at the 56th Annual Scientific Meeting of the Retina Society • PR Newswire (US) • 10/11/2023 10:00:00 AM
- Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare Conference • PR Newswire (US) • 09/08/2023 10:00:00 AM
- New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusion • PR Newswire (US) • 09/07/2023 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/17/2023 09:26:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:33:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:12:57 PM
- Kodiak Sciences Announces Second Quarter 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 08/14/2023 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/24/2023 10:45:38 AM
- Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program • PR Newswire (US) • 07/24/2023 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/03/2023 08:24:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/03/2023 08:22:39 PM
- Kodiak Sciences to Present at Upcoming Investor Conferences • PR Newswire (US) • 05/30/2023 08:15:00 PM
- Kodiak Sciences Announces First Quarter 2023 Financial Results and Recent Business Highlights • PR Newswire (US) • 05/15/2023 08:01:00 PM
- Kodiak Sciences Announces Upcoming Presentations on its Product and Research Pipeline at ARVO 2023 Annual Meeting • PR Newswire (US) • 04/21/2023 11:30:00 AM
- Kodiak Sciences Expands Development Pipeline with Treatment of First Patient in Phase 1 Clinical Study of KSI-501, an Investigational Bispecific Antibody Biopolymer Conjugate for Retinal Diseases • PR Newswire (US) • 04/03/2023 11:30:00 AM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM